![]() |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
Alnylam Reports Positive Phase I Data on ATTR Drug; Sees Pfizer Drug Setback as FDA Guide
New to GenomeWeb? Register here quickly.
